Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Dr. Reddy’s Aims For Rituximab, Peg-GCSF Biosimilars In U.S.

This article was originally published in PharmAsia News

Executive Summary

The Indian drug maker said it received approvals to conduct safety studies for two biosimilars and is working closely with the regulatory agencies. Analysts expect the trials may take roughly three years following which it will be ready for the product approvals in the U.S. market.

Advertisement

Related Content

Biosimilar Draft Guidance Outlines Three-Arm Bridging Studies For Non-U.S. Products
With Filgrastim, Rituximab And Darebepoetin Alfa Under Its Belt, India's Dr. Reddy's Set To Launch Fourth Biosimilar - Pegfilgrastim

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC087084

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel